{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T03:22:56Z","timestamp":1777605776043,"version":"3.51.4"},"reference-count":18,"publisher":"Japanese Society of Internal Medicine","issue":"23","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2023,12,1]]},"DOI":"10.2169\/internalmedicine.1369-22","type":"journal-article","created":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T22:13:39Z","timestamp":1682028819000},"page":"3501-3506","source":"Crossref","is-referenced-by-count":9,"title":["Marked Increase in Urinary C-peptide Levels after Treatment with Sacubitril\/Valsartan in Patients with Type 2 Diabetes Mellitus and Hypertension"],"prefix":"10.2169","volume":"62","author":[{"given":"Yasuhiro","family":"Tanji","sequence":"first","affiliation":[{"name":"Division of Metabolism and Diabetes, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shojiro","family":"Sawada","sequence":"additional","affiliation":[{"name":"Division of Metabolism and Diabetes, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaki","family":"Numahata","sequence":"additional","affiliation":[{"name":"Division of Metabolism and Diabetes, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taichi","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Division of Metabolism and Diabetes, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Munakata","sequence":"additional","affiliation":[{"name":"Division of Metabolism and Diabetes, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Akai","sequence":"additional","affiliation":[{"name":"Division of Metabolism and Diabetes, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 79: 1757-1780, 2022."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Docherty KF, Vaduganathan M, Solomon SD, McMurray JJV. Sacubitril\/valsartan: neprilysin inhibition 5 years after PARADIGM-HF. JACC Heart Fail 8: 800-810, 2020.","DOI":"10.1016\/j.jchf.2020.06.020"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Tsutsui H, Ide T, Ito H, et al.; the Japanese Heart Failure Society Joint Working Group. JCS\/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure. Circ J 85: 2252-2291, 2021.","DOI":"10.1253\/circj.CJ-21-0431"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Willard JR, Barrow BM, Zraika S. Improved glycaemia in high-fat-fed neprilysin-deficient mice is associated with reduced DPP-4 activity and increased active GLP-1 levels. Diabetologia 60: 701-708, 2017.","DOI":"10.1007\/s00125-016-4172-4"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. D&apos;Elia E, Iacovoni A, Vaduganathan M, Lorini FL, Perlini S, Senni M. Neprilysin inhibition in heart failure: mechanisms and substrates beyond modulating natriuretic peptides. Eur J Heart Fail 19: 710-717, 2017.","DOI":"10.1002\/ejhf.799"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Seferovic JP, Claggett B, Seidelmann SB, et al. Effect of sacubitril\/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol 5: 333-340, 2017.","DOI":"10.1016\/S2213-8587(17)30087-6"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. Gjessing HJ, Matzen LE, Faber OK, Fr\u00f8land A. Fasting plasma C-peptide, glucagon stimulated plasma C-peptide, and urinary C-peptide in relation to clinical type of diabetes. Diabetologia 32: 305-311, 1989.","DOI":"10.1007\/BF00265547"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8. Henriksen JH, Tronier B, B\u00fclow JB. Kinetics of circulating endogenous insulin, C-peptide, and proinsulin in fasting nondiabetic man. Metabolism 36: 463-468, 1987.","DOI":"10.1016\/0026-0495(87)90044-8"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Turner AJ. 108 - Neprilysin. In: Handbook of Proteolytic Enzymes. 2nd ed. Barrett AJ, Rawlings ND, Woessner JF, Eds. Academic Press, London, 2004: 419-426.","DOI":"10.1016\/B978-0-12-079611-3.50116-6"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Varandani PT, Shroyer LA. Degradation of proinsulin and isolated C-peptide by rat kidney neutral metallo-endopeptidase. Biochim Biophys Acta 661: 182-190, 1981.","DOI":"10.1016\/0005-2744(81)90002-4"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Nishiya Y, Daimon M, Mizushiri S, et al. Neprilysin inhibitor may increase urinary C-peptide excretion. Diabetes Care 45: e122-e123, 2022.","DOI":"10.2337\/dc22-0538"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Araki E, Goto A, Kondo T, et al. Japanese Clinical Practice Guideline for Diabetes 2019. J Diabetes Investig 11: 1020-1076, 2020.","DOI":"10.1111\/jdi.13306"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab 46: 101102, 2021.","DOI":"10.1016\/j.molmet.2020.101102"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Oh J, Kim JH, Park HD. Clinical utility and cross-reactivity of insulin and C-peptide assays by the lumipulse G1200 system. Ann Lab Med 38: 530-537, 2018.","DOI":"10.3343\/alm.2018.38.6.530"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Nalivaeva NN, Zhuravin IA, Turner AJ. Neprilysin expression and functions in development, ageing and disease. Mech Ageing Dev 192: 111363, 2020.","DOI":"10.1016\/j.mad.2020.111363"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Dogra GK, Herrmann S, Irish AB, Thomas MA, Watts GF. Insulin resistance, dyslipidaemia, inflammation and endothelial function in nephrotic syndrome. Nephrol Dial Transplant 17: 2220-2225, 2002.","DOI":"10.1093\/ndt\/17.12.2220"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Heck PM, Dutka DP. Insulin resistance and heart failure. Curr Heart Fail Rep 6: 89-94, 2009.","DOI":"10.1007\/s11897-009-0014-8"},{"key":"18","first-page":"e535","volume":"134","author":"B Bozkurt","year":"2016","unstructured":"18. Bozkurt B, Aguilar D, Deswal A, et al. Contributory risk and management of comorbidities of hypertension, obesity, diabetes mellitus, hyperlipidemia, and metabolic syndrome in chronic heart failure: a scientific statement from the American Heart Association. Circulation 134: e535-e578, 2016.","journal-title":"Circulation","ISSN":"https:\/\/id.crossref.org\/issn\/0009-7322","issn-type":"print"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/23\/62_1369-22\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T03:18:57Z","timestamp":1701487137000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/23\/62_1369-22\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,1]]},"references-count":18,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.1369-22","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,1]]},"article-number":"1369-22"}}